FIA
TGTX icon

FNY Investment Advisers’s TG Therapeutics TGTX Stock Holding History

FNY Investment Advisers’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-409
Closed -$14K – 1464
2025
Q3 		$14K Buy
+409
New +$13.5K ﹤0.01% 743

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

FNY Investment Advisers's TGTX Position: Q4 2025 in Review

FNY Investment Advisers sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 409 shares — an estimated $14K sold.

FNY Investment Advisers first reported a position in TGTX in Q3 2025 and held it in 1 quarter. The position peaked at $14K in Q3 2025. 351 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

  • FNY Investment Advisers reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 409 TG Therapeutics shares in Q4 2025, an estimated $14K.
  • FNY Investment Advisers first reported a position in TG Therapeutics in Q3 2025 and held it in 1 quarter.
  • FNY Investment Advisers's TG Therapeutics position peaked at $14K in Q3 2025.
  • 351 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on FNY Investment Advisers's 13F filing for Q4 2025, filed 16 Jan 2026.